Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Boxeprazine; GBR-12909

Latest Information Update: 19 Jan 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gist-Brocades
  • Developer Laguna Pharmaceuticals; Novo Nordisk
  • Class Antidepressants; Antiparkinsonians; Piperazines; Small molecules
  • Mechanism of Action Dopamine plasma membrane transport protein antagonists; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atrial fibrillation; Cocaine abuse; Major depressive disorder; Parkinson's disease; Peptic ulcer

Most Recent Events

  • 04 Dec 2015 Discontinued - Phase-III for Atrial fibrillation in USA, Bulgaria, Hungary, Israel, Netherlands, Poland and Russia (PO)
  • 01 Sep 2015 Phase-III clinical trials in Atrial fibrillation in USA, Russia, Israel, Bulgaria, Hungary (PO)
  • 06 Jun 2015 Laguna Pharmaceuticals plans a phase III trial in Atrial fibrillation in USA (NCT02454283)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top